Category - Developments

Developments

Entera reports positive data for oral GLP-2 tablet for SBS at 2025 ESPEN Congress

Entera Bio (NASDAQ: ENTX) has announced the presentation of a poster highlighting pharmacokinetic data relating to its first-in-class oral GLP-2 analog program for the treatment of short bowel syndrome (SBS), at the...

September 16, 2025

Developments

Cocrystal showcases potential first oral antiviral for norovirus

Cocrystal Pharma (NASDAQ: COCP) has announced that the scientific foundation and clinical progress of its lead pan-viral protease inhibitor, CDI-988, was discussed by President and CEO, Dr. Sam Lee, in a presentation at...

September 12, 2025

Developments

Karyopharm completes enrollment of Phase 3 SENTRY trial in MF

Karyopharm Therapeutics (NASDAQ: KPTI) has announced enrollment completion in its Phase 3 SENTRY trial, designed to evaluate selinexor in combination with ruxolitinib in JAKi-naïve myelofibrosis (MF) patients. According...

September 10, 2025

Developments

BioXcel announces positive topline data for BXCL501 in bipolar and schizophrenia

BioXcel Therapeutics (NASDAQ: BTAI) has announced positive topline exploratory efficacy data from its SERENITY At-Home pivotal Phase 3 safety trial of BXCL501 (IGALMI) for agitation associated with bipolar disorders or...

September 10, 2025

Developments

FDA grants Greenwich fast track designation for GLSI-100

Greenwich LifeSciences (NASDAQ: GLSI) announced that the FDA has granted GLSI-100 fast track designation for the treatment of patients with HLA-A*02 genotype and HER2-positive breast cancer who have completed treatment...

September 10, 2025

Developments

Perimeter Joins ASBrS Industry Relations Council

Perimeter Medical Imaging AI (TSX-V:PINK; OTCQX: PYNKF) announced that it has joined the American Society of Breast Surgeons (ASBrS) Industry Relations Council (IRC). The ASBrS is the primary leadership organization for...

September 8, 2025

Developments

iMDX launches novel registry database; reports positive strategic update

Insight Molecular Diagnostics (iMDX) (NASDAQ: IMDX) has announced a positive strategic update and novel registry to gather real-world data on patient experiences and outcomes concerning its flagship kidney transplant...

September 8, 2025

Developments

Pasithea enrolls Cohort 2 for trial of PAS-004 in NF1 after SRC review

Pasithea Therapeutics (NASDAQ: KTTA) announced that the Safety Review Committee (SRC) has recommended its Phase 1/1b open label study to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of PAS-004...

September 8, 2025

Developments

Firefly partners with HealingMaps to offer cognitive electrophysiology analytics to 2500+ clinics across North America

Firefly Neuroscience (NASDAQ: AIFF) announced a new partnership with HealingMaps the leading directory for ketamine, psychedelic-assisted therapy, and transcranial magnetic stimulation (TMS) clinics, and Advanced...

September 5, 2025

Developments

Health Canada grants Palisade NOL for trial of PALI-2108 in FSCD

Palisade Bio (NASDAQ: PALI) has announced receiving a No Objection Letter (NOL) from Health Canada for its clinical trial application to evaluate PALI-2108, a first-in-class, ileocolonic-targeted PDE4 B/D inhibitor, in...

September 5, 2025

Category - Developments

Subscribe